RevOpsis
RevOpsis Therapeutics is a next-generation biopharmaceutical company developing multispecific antibody therapies using its proprietary Rev-Mod Platform. Its lead asset RO-104 is a trispecific biologic targeting retinal vascular diseases including neovascular age-related macular degeneration. Based in Dover, Delaware with 2-10 employees.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2023
Create a free account to see which investors have funded this company.
Create Free AccountClinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...
Belgian agricultural biotech company developing microbial-based biocontrol and biostimulant produ...
Clinical-stage biotechnology company developing in vivo CRISPR gene editing therapies for severe ...
Biotech company developing novel GPCR-targeting therapeutics using conformation-specific nanobodies.
UK biotech developing cell conversion technology for life-saving cell therapies.
